Fluorescence bioimaging of drug nanocarriers based on Förster resonance energy transfer, aggregation-induced emission and aggregation-caused quenching
Zhang R., He H., Lu Y., Raza A., Wu W.
Narrative Review, published in Acta Pharm Sin B (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Acta Pharm Sin B (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 42039291
- PMCID
- PMC13104681
- DOI
- 10.1016/j.apsb.2025.10.023
- Citations
- 1
Abstract (original English)
The introduction of environment-responsive probes has greatly improved the accuracy of fluorescence bioimaging in evaluating drug nanocarriers. This review highlights the key roles of Förster resonance energy transfer, aggregation-induced emission, and aggregation-caused quenching in advancing nanomedicine. These technologies have enhanced our understanding of nanocarrier pharmacokinetics, biodistribution, and intracellular behavior, providing valuable insights for optimizing drug delivery systems. Their integration into imaging platforms has enabled precise monitoring of nanocarriers in complex biological environments. This review outlines detailed progress in the use of environment-responsive probes, emphasizing their importance in improving the design and effectiveness of nanomedicines. Looking forward, advances in probe engineering and multimodal imaging, combined with computational tools, are expected to drive the development of more targeted, efficient, and personalized therapeutic strategies.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.